Inherited genetic variation and overall survival following follicular lymphoma.
ABSTRACT Follicular lymphoma (FL) has variable progression and survival, and improved identification of patients at high risk for progression would aid in identifying patients most likely to benefit from alternative therapy.In a sample of 244 FL cases identified during a population-based case-control study of non-Hodgkin lymphoma (NHL), we examined 6,679 tag SNPs in 488 gene regions for associations with overall FL survival. Over a median follow-up of 89 months with 65 deaths in this preliminary study, we identified 5 gene regions (BMP7, GALNT12,DUSP2, GADD45B, and ADAM17) that were associated with overall survival from FL. Results did not meet the criteria for statistical significance after adjustment for multiple hypothesis testing. These results,which support a role for host factors in determining the variable progression of FL, serve as an initial examination that can inform future studies of genetic variation and FL survival. However, they require replication in independent populations, as well as assessment in rituximab-treated patients.
- [Show abstract] [Hide abstract]
ABSTRACT: There is growing evidence linking genetic variations to non-Hodgkin lymphoma (NHL) etiology. To complement ongoing agnostic approaches for identifying susceptibility genes, we evaluated 488 candidate gene regions and their relation to risk for NHL and NHL subtypes. We genotyped 6,679 tag single nucleotide polymorphisms (SNPs) in 947 cases and 826 population-based controls from a multicenter U.S. case-control study. Gene-level summary of associations were obtained by computing the minimum P value ("minP test") on the basis of 10,000 permutations. We used logistic regression to evaluate the association between genotypes and haplotypes with NHL. For NHL subtypes, we conducted polytomous multivariate unconditional logistic regression (adjusted for sex, race, age). We calculated P-trends under the codominant model for each SNP. Fourteen gene regions were associated with NHL (P < 0.01). The most significant SNP associated with NHL maps to the SYK gene (rs2991216, P-trend = 0.00005). The three most significant gene regions were on chromosome 6p21.3 (RING1/RXRB; AIF1; BAT4). Accordingly, SNPs in RING1/RXRB (rs2855429), AIF1 (rs2857597), and BAT4 (rs3115667) were associated with NHL (P-trends ≤ 0.0002) and both diffuse large B-cell and follicular lymphomas (P-trends < 0.05). Our results suggest potential importance for SYK on chromosome 9 with NHL etiology. Our results further implicate 6p21.3 gene variants, supporting the need for full characterization of this chromosomal region in relation to lymphomagenesis. Gene variants on chromosome 9 may represent a new region of interesting for NHL etiology. The independence of the reported variants in 6p21.3 from implicated variants (TNF/HLA) supports the need to confirm causal variants in this region.Cancer Epidemiology Biomarkers & Prevention 01/2011; 20(1):42-9. · 4.56 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: The natural history of follicular lymphoma is believed not to have changed over the last 30 years. Median survivals have ranged from 7 to 10 years, and the disease is considered incurable. However, multiple new treatment options have been developed in the last decade, and their impact on survival of follicular lymphoma remains unknown. In the current analysis, we identified all previously untreated, advanced-stage, follicular lymphoma patients treated with the following three sequential treatment approaches: cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy +/- nonspecific immunostimulants (Southwest Oncology Group [SWOG] 7426 and 7713: 1974 to 1983); prednisone, methotrexate, doxorubicin, cyclophosphamide, and etoposide (ProMACE) plus mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) +/- interferon (SWOG 8809: 1988 to 1994); and CHOP followed by monoclonal antibody (MoAb) therapy (SWOG 9800 and 9911: 1998 to 2000). We assessed the patients' progression-free survival (PFS) and overall survival (OS). The MoAb trials included CHOP followed by rituximab (SWOG 9800) and CHOP followed by (131)I-tositumomab (SWOG 9911). The PFS curves for the CHOP and ProMACE-MOPP studies are overlapping, with 4-year PFS estimates of 46% and 48%, respectively. However, the PFS rate of the CHOP + MoAb studies is significantly improved at 61% (P = .005). The OS curves show improvement with each succeeding study. The 4-year estimate of OS is 69% for the CHOP regimens, 79% for the ProMACE-MOPP study, and 91% for the CHOP + MoAb regimens (P < .001). These conclusions were retained after adjusting for differences in prognostic factors between the study groups. The results of this study suggest that OS for patients with follicular lymphoma has improved over time and that the choice of initial therapy may matter.Journal of Clinical Oncology 12/2005; 23(33):8447-52. · 18.04 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: To examine outcome of treatment for patients with recurrent follicular lymphoma. Two hundred twelve newly diagnosed follicular lymphoma patients were studied. One hundred seventy-nine were initially treated successfully. Recurrent or progressive lymphoma developed in 116. Treatment was given according to disease stage and current protocols, mostly with single alkylating agents. A policy of repeated lymph node and bone marrow biopsy was pursued. The overall median survival duration was 9 years, with a median follow-up duration of 12 years. Following recurrence, the median survival duration was 4 1/2 years. Only eight of 116 patients with recurrent disease died of causes unrelated to lymphoma. The overall response rate to first re-treatment was 78% and showed slight decline with successive recurrences, reaching 48% after the fourth treatment. The median duration of second remission was 13 months, (v 31 months for first remission), with the only significant predictive factor being quality of remission. Multivariate analysis showed only age at recurrence and number of prior treatments to correlate with survival after first recurrence. Survival after second remission was only correlated with age and quality of response: Kaplan-Meier estimates gave 53% of patients reaching second complete remission alive 10 years later, compared with 28% in partial remission. Age and previous and continuing responsiveness of follicular lymphoma to therapy are the principal determinants of survival following recurrence. Improvement in survival with new treatments will be demonstrated most readily in older patients, while more intensive approaches should be tested in younger patients in whom remission is achieved with difficulty.Journal of Clinical Oncology 02/1995; 13(1):140-7. · 18.04 Impact Factor
4. Nieto WG, Almeida J, Romero A, et al. Primary Health Care Group of Sala-
manca for the Study of MBL. Increased frequency (12%) of circulating chronic
lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sen-
sitive multicolor flow cytometry approach. Blood 2009;114:33–37.
5. Mowery YM, Lanasa MC. Clinical aspects of monoclonal B-cell lymphocyto-
sis. Cancer Control 2012;19:8–17.
6. Rawstron AC, Bennet F, Hillmen P. The biological and clinical relationship
between CD51231 monoclonal B-cell lymphocytosis and chronic lymphocytic
leukaemia. Br J Haematol 2007;139:724–729.
7. Mulligan CS, Thomas ME, Mulligan SP. Reply to Monoclonal B-cell lymphocyto-
sis and chronic lymphocytic leukemia. N Engl J Med 2008;359:2065–2066.
8. Rossi D, Sozzi E, Puma A, et al. The prognosis of clinical monoclonal B
cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic
leukaemia and is recapitulated by biological risk factors. Br J Haematol
9. Shanafelt TD, Ghia P, Lanasa MC, Landgren O, Rawstron AC. Monoclonal B-
cell lymphocytosis (MBL): biology, natural history and clinical management.
10. Landgren O, Albitar M, Ma W, et al.
chronic lymphocytic leukemia. N Engl J Med 2009;360:659–667.
11. Rawstron AC, Bennett FL, O’Connor SJ, et al. Monoclonal B-cell lymphocyto-
sis and chronic lymphocytic leukemia. N Engl J Med 2008;359:575–583.
12. Shanafelt TD, Kay NE, Rabe KG, et al. Natural history of individuals with clini-
cally recognized monoclonal B-cell lymphocytosis compared with patients with
Rai 0 chronic lymphocytic leukemia. J Clin Oncol 2009;27:3959–3963.
13. Almeida J, Nieto WG, Teodosio C, et al. CLL-like B-lymphocytes are system-
atically present at very low numbers in peripheral blood of healthy adults.
14. Palmer S, Hanson CA, Zent CS, et al. Prognostic importance of T and NK-
cells in a consecutive series of newly diagnosed patients with chronic lympho-
cytic leukaemia. Br J Haematol 2008;141:607–614.
B-cell clones as early markers for
15. Caraux A, Klein B, Paiva B, et al.
(MSCNET). Circulating human B and plasma cells. Age-associated changes
in counts and detailed characterization of circulating normal CD138- and
CD1381 plasma cells. Haematologica 2010;95:1016–1020.
16. Perez-Andres M, Paiva B, Nieto WG, et al.
compartments: a crossroad in B-cell traffic. Cytometry B Clin Cytom 2010;78:
17. Mizutani H, Katagiri S, Uejima K, et al. T-cell abnormalities in patients with
idiopathic thrombocytopenic purpura: the presence of OKT4181 cells. Scand
J Haematol 1985;35:233–239.
18. Bachetoni A, Lionetti P, Cinti P, et al.
cytes into kidney allografts during tubular necrosis or rejection. Clin Trans-
19. D’Arena G, Rossi G, Minervini MM, et al.
monoclonal B-cell lymphocytosis. Int J Immunopathol Pharmacol 2011;24:
20. Fazi C, Scarfo b0L, Pecciarini L, et al. General population low-count CLL-like
MBL persists over time without clinical progression, though carrying the same
cytogenetic abnormalities of CLL. Blood 2011;118:6618–6625.
21. Johnston LA. Competitive interactions between cells: death, growth, and
geography. Science 2009;324:1679–1682.
22. Vogt RF, Shim YK, Middleton DC, et al. Monoclonal B-cell lymphocytosis as
a biomarker in environmental studies. Br J Haematol 2007;139:690–700.
23. Perfetto SP, Ambrozak D, Nguyen R et al.
matic flow cytometry. Nat Protoc 2006;1:1522–1530.
24. Nieto WG, Teodosio C, Lo ´pez A, et al. Non-CLL-like monoclonal B-cell lym-
phocytosis (MBL) in the general population: prevalence and phenotypic/
genetic characteristics. Clinical Cytometry 2010;78:S24–34.
25. Shim YK, Middleton DC, Caporaso NE, et al.
B-cell lymphocytosis: a systematic review. Cytometry Part B 2010;78:
for the Myeloma Stem Cell Network
Human peripheral blood B-cell
Homing of CD41CD561 T lympho-
Circulating regulatory T cells in
Quality assurance for polychro-
Prevalence of monoclonal
Inherited genetic variation and overall survival following
Todd M. Gibson,1,2* Sophia S. Wang,3James R. Cerhan,4Matthew J. Maurer,4Patricia Hartge,1
Thomas M. Habermann,4Scott Davis,5,6Wendy Cozen,7,8Charles F. Lynch,9Richard K. Severson,10,11
Nathaniel Rothman,1Stephen J. Chanock,1,12and Lindsay M. Morton1
Follicular lymphoma (FL) has variable progression and survival, and
improved identification of patients at high risk for progression would
aid in identifying patients most likely to benefit from alternative ther-
apy. In a sample of 244 FL cases identified during a population-based
case-control study of non-Hodgkin lymphoma (NHL), we examined
6,679 tag SNPs in 488 gene regions for associations with overall FL
survival. Over a median follow-up of 89 months with 65 deaths in this
preliminary study, we identified 5 gene regions (BMP7, GALNT12,
DUSP2, GADD45B, and ADAM17) that were associated with overall sur-
vival from FL. Results did not meet the criteria for statistical signifi-
cance after adjustment for multiple hypothesis testing. These results,
which support a role for host factors in determining the variable pro-
gression of FL, serve as an initial examination that can inform future
studies of genetic variation and FL survival. However, they require
replication in independent populations, as well as assessment in
Follicular lymphoma (FL) is one of the most common subtypes of NHL,
with over 24,000 new cases diagnosed each year in the United States
[1,2]. Prior to the rituximab era, FL had a median survival of ?10 years,
but progression varied and survival ranged from <1 year to >20 years
after diagnosis . Deaths from FL follow resistance to treatments or
transformation to a more aggressive lymphoma type, usually diffuse large
B-cell lymphoma (DLBCL) . The Follicular Lymphoma International Prog-
nostic Index (FLIPI) separates FL patients into three risk groups based on
age, stage of disease, concentrations of b2-microglobulin and hemoglobin,
nodal area involvement, serum lactate dehydrogenase levels, and bone
marrow involvement [5,6]. Treatment strategies for FL have included
‘‘watchful waiting,’’ chemotherapy,
radioimmunoconjugates, and stem cell transplantation . Although new
treatment strategies have changed the survival of patients with FL, patients
continue to die from disease or complications of survival from disease .
Improved identification of patients at high risk for progression would aid in
developing targeted approaches for those that might benefit from alterna-
tive therapeutic interventions.
The heterogeneous survival times among FL patients reflects genetic
properties of the tumors, but the immune microenvironment likely plays a
significant role as well [8,9]. We hypothesized that germline genetic variation
could also influence FL survival due to differences in repair or clearance of
genetic damage, immune response, inflammatory response, or other proc-
esses . We previously reported associations between overall survival of
FL and common genetic variants in cytokine genes (IL8, IL2, IL12B, and
IL1RN) and one-carbon metabolism genes (MTHFR, FTHFD, and GGH) in
studies of ?100 candidate single nucleotide polymorphisms (SNPs) from 88
genes [10,11]. Because numerous pathways and processes have been
implicated in histologic transformation and overall prognosis of FL [8,12], we
conducted a broad, exploratory study of the association of 488 candidate
genes with overall survival. Genes were selected for their potential to influ-
ence lymphoma survival based on a literature review [8,13–15], and we
comprehensively tagged these genes/gene regions with 6,679 SNPs.
TABLE I. Summary of Gene-Level and SNP-Level Association Tests for
Genes Associated With Overall Survivalain Follicular Lymphoma Patients at
P < 0.01
Tag SNP with
aDichotomous survival: yes/no.
bDetermined using principal components analysis.
cAdjusted for multiple hypothesis testing using the false discovery rate.
dCox proportional hazards models.
724American Journal of Hematology
The median age at diagnosis of the 244 FL cases was 56 years, and
42% were age 60 or older. Patients were predominantly white (91%) with
similar numbers of men and women (49% female). Participants who
reported Hispanic ethnicity (n 5 10) were categorized based on self-
reported race; eight were included in the ‘‘white’’ category and two in the
‘‘other’’ category. The majority of FL cases were diagnosed with advanced
stage disease (56%), 14% reported B symptoms, and the most common
treatments were chemotherapy-based regimens (63%), observation (25%),
and radiation only (11%). Over a median follow-up of 89 months (range,
9–112 months), 65 (27%) patients died of any cause, with 75% of these
having lymphoma coded as the underlying cause of death. As described
previously, the observed survival for patients in our study was similar to
that observed in the SEER program . The risk score constructed to
capture effects of the above clinical and demographic factors was signifi-
cantly associated with overall survival (HR 5 3.10, 95% CI 5 2.08–6.60)
in a Cox model.
Among the 488 gene regions examined, we identified five independent
gene regions that were associated (P < 0.01) with FL overall survival (Table
I) prior to adjustment for multiple hypothesis testing. The two regions with
the smallest gene-based P values were BMP7 and GALNT12 (P 5 0.002),
but neither gene region was significantly associated with survival after FDR
adjustment (FDR; P 5 0.41). Other gene regions of interest included
DUSP2, GADD45B, and ADAM17, but again associations were not signifi-
cant after FDR adjustment. In analysis of individual SNPs (Table II), four
SNPs were associated with survival at a Ptrend< 0.001. A SNP in the BMP7
gene (rs6025446, Ptrend 5 0.00003; FDR P 5 0.22) had the lowest
observed P value for association and was significantly associated with
improved overall survival after adjustment for clinical and demographic fac-
tors (HRAG5 0.41, 95% CI 5 0.21–0.69; HRGG5 0.17, 95% CI 5 0.05–
0.54). As with the gene-based tests, none of the SNP associations remained
significant after adjustment for multiple hypothesis testing. Other SNPs with
suggestive associations that may be of interest for follow-up studies are
shown in Table II, and genotype frequencies and associations with overall
survival for all 6,679 SNPs examined are available in Supporting Information
Table SI. The SNP associations reported in Table II were similar when the
same models were used with outcomes restricted to death from follicular
lymphoma (Supporting Information Table SII).
In a sample of 244 FL cases identified during a population-based case-
control study of NHL, we identified five gene regions (BMP7, GALNT12,
DUSP2, GADD45B, and ADAM17) that were associated with overall survival
from FL after accounting for clinical and demographic factors. In addition to
SNPs located within the five associated gene regions, a SNP in the IRF2
gene was also associated with FL overall survival. In this exploratory investi-
gation of a large number of genetic variants (>450 genes) and survival after
FL, results did not meet the criteria for significance after adjustment for mul-
tiple hypothesis testing, thus replication in other populations is critical.
Nevertheless, our results suggest a small number of gene regions that may
be of particular interest in future studies of survival after FL.
The gene regions identified in our study can all be linked to regulation of
growth factors and cell signaling pathways, and expression levels have been
associated with FL survival or control of B-cell activity [8,13]. The bone mor-
phogenetic protein encoded by BMP7 is known to induce apoptosis, inhibit
proliferation, and inhibit metastasis of a number of cancer cell types through
antagonism of TGF-b pathways . ADAM17 gene products have protei-
nase activity and are responsible for membrane-shedding of TGF-b and
other growth-regulators . GADD45B has been identified as a prosurvival
factor for tumors that mediates activation of the mitogen-activated protein
kinase (MAPK) p38/JNK pathway . DUSP2 encodes a dual-specificity
phosphatase that can inhibit MAPK activity via dephosphorylation and is
involvedin regulationof immune
GALNT12 mutations are associated with aberrant glycosylation, which is a
feature of many cancers and can affect cell growth and differentiation
[20,21]. The associations observed in this study may suggest that inherited
differences in growth-regulatory pathways in immune cells can impact the
phenotype and progression of FL, but FDR-adjusted P values were not sig-
nificant and replication in further studies is required. The variants identified
are tag SNPs, and none of the identified SNPs are located within coding
exons. The most significant SNP in DUSP2 is located in the 30UTR, and
while rs4806857 tags variation in GADD45B, it is located almost 10-kb 30of
the coding region. If additional studies find associations between these
genes and survival after FL, then further work to evaluate functional conse-
quences of specific variants may be warranted.
This study examines associations with FL survival for more genetic var-
iants than any reported to date, and our tag SNP approach provides a more
comprehensive assessment of genetic variation in these genes and sur-
rounding regions. The genes included in the study were selected a priori
based on existing literature and knowledge of lymphoma mechanisms. Rig-
orous quality control procedures ensured high quality genotype data, and
our statistical analyses accounted for linkage among SNPs and the large
number of genes/SNPs examined. The population-based ascertainment and
rapid-reporting mechanisms employed to identify new FL cases provided a
study population likely to be generalizable, as suggested by similarities to
the mortality observed in SEER .
An important limitation of our study is the lack of detailed treatment data
and limited information on prognostic factors, although our clinical risk score
predicted at a similar level to FLIPI . Rituximab was not yet widely used
as an initial FL therapy at the time of the case-control study, so treatment of
patients in our study was different from current practice . Despite the
use of rapid reporting mechanisms, some of the most aggressive cases of
FL were not included in our study. An analysis of FL etiology in the same
case-control study did not find associations for the SNPs reported here ,
which may suggest involvement of different factors in FL etiology and prog-
nosis, although replication is needed.
The gene variants reported here have not previously been linked to FL,
and we have made numerous comparisons. These results therefore serve
as an important initial examination that can inform future studies, but require
replication in independent populations, as well as assessment in rituximab-
treated patients. Further investigation is warranted, as identification of inher-
ited genetic variants that affect FL prognosis could yield new insights into
clinical outcomes and treatment options.
and inflammatory responses .
Materials and Methods
Patients included 244 FL cases identified in a population-based case-con-
trol study of NHL in the United States, details of which have been reported
previously [10,23]. Briefly, 20- to 74-year-old patients with histologically con-
firmed NHL and without known HIV infection were identified from four sur-
veillance, epidemiology, and end results (SEER) cancer registries (Detroit,
MI; Seattle/Puget Sound, Washington; Los Angeles, CA; Iowa) between July
1998 and June 2000. Each of the recruitment centers obtained local IRB
approval for the study, the overall study was approved by the National Insti-
tutes of Health, and all participants provided written informed consent.
Patients with FL were identified using the International Classification of Dis-
eases—Oncology (ICD-O), 3rd edition  codes: 9690–9693, 9695–9698.
Patients provided data on age, sex, race, Hispanic ethnicity, and education
TABLE II. Individual SNPs Most Strongly Associated With Overall Survivalain Follicular Lymphoma Patients (Ptrend< 0.001)
Tag SNP with smallest Ptrend
Heterozygous for minor alleleHomozygous for minor allele
dbSNP IDMinor allele/MAFNHR (95% CI)b
NHR (95% CI)b
aDichotomous survival: yes/no.
bAdjusted for prognostic risk score; HR based on Cox proportional hazards models with ‘‘homozygous for major allele’’ as the reference group.
cAdjusted for multiple hypothesis testing using the false discovery rate.
American Journal of Hematology 725
level via interviews conducted for the case-control study. Linkage to routine
follow-up from SEER registry databases at each study site in the spring of
2008 provided information on histology, stage, presence of B-symptoms,
date of last follow-up, vital status, and first course of therapy (use of single
or multiagent chemotherapy, radiation, other therapies exclusive of chemo-
therapy and/or radiation, and no therapy or observation); information on indi-
vidual agents or doses was not available.
DNA was extracted from blood clots, buffy coats, or buccal cell sam-
ples as described previously , and genotype frequencies were equiva-
lent for individuals who provided blood or buccal cell samples . Geno-
typing of 7,943 tag SNPs from 488 gene regions putatively involved in
lymphoma survival was conducted at the NCI Core Genotyping Facility as
previously described . Tag SNPs were selected within the region
spanning 20-kb 50of the transcription start site to 10-kb 30of the end of
the last exon and were grouped using r2> 0.80 to define a gene region.
Genotyping was successfully completed for 6,830 tag SNPs. Of these,
SNPs with a low completion rate (<90% of samples) or with a concord-
ance <95% in QC samples were also excluded, resulting in a final ana-
lytic study population of 244 FL cases with data for 6,679 SNPs. Of the
1,321 cases in the case-control study, 1,286 had valid registry data at
the time of linkage, of which 328 were FL. Of the 328 FL cases, 50
were excluded because they did not provide a blood or buccal sample
and 34 were excluded based on genotyping QC. This left a total of 244
FL cases for analysis.
We examined the association between individual SNPs and overall sur-
vival in FL patients by time-to-event analysis using multivariable Cox pro-
portional hazards regression models to estimate hazard ratios (HRs) and
95% confidence intervals (95% CI). Models were adjusted for a prognos-
tic risk score generated by the linear combination of the following clinical
and demographic variables multiplied by their Cox regression coefficients:
stage (local, regional, distant, missing), presence of B-symptoms (yes, no,
missing), type of initial therapy (chemotherapy 1 radiation, chemotherapy
1 other therapy, radiation only, no therapy), age (<60 years, 601 years,
as categorized in FLIPI), sex, race (white, all other), study center (Detroit,
Iowa, Los Angeles, Seattle), and years of education (<12, 12–15, 161
years) . We examined associations at the gene level using principal
components analysis as described previously . Briefly, linear combina-
tions of ordinally scaled SNPs were used to identify principal components
that explained ?90% of the SNP variance within the gene region. The
principal components were then included in multivariable Cox proportional
hazards regression models . To address the potential for Type I error
due to multiple comparisons, we calculated the false discovery rate (FDR)
for individual SNPs and gene-level tests. The FDR is defined as the
expected proportion of falsely rejected hypotheses among all rejected
hypotheses . A secondary analysis restricted to lymphoma-specific
death was conducted for genes and SNPs associated with overall
1Division of Cancer Epidemiology and Genetics, Department of Health and Human
Services, National Cancer Institute, National Institutes of Health,
Rockville, Maryland;2Department of Health and Human Services, Cancer
Prevention Fellowship Program, Center for Cancer Training, National Cancer
Institute, National Institutes of Health, Rockville, Maryland;3Division of Cancer
Etiology, Department of Population Sciences, Beckman Research Institute and the
City of Hope, Duarte, California;4Division of Epidemiology, Mayo Clinic College of
Medicine, Rochester, Minnesota;5Program in Epidemiology, Fred Hutchinson
Cancer Research Center, Seattle, Washington;6Department of Epidemiology,
University of Washington, Seattle, Washington;7Department of Preventive
Medicine, Keck School of Medicine, University of Southern California, Los
Angeles, California;8Department of Pathology, Keck School of Medicine,
University of Southern California, Los Angeles, California;9Department of
Epidemiology, University of Iowa, Iowa City, Iowa;10Department of Family
Medicine and Public Health Sciences, Wayne State University, Detroit, Michigan;
11Karmanos Cancer Institute, Detroit, Michigan;12Core Genotyping Facility,
Division of Cancer Epidemiology and Genetics, Department of Health and Human
Services, National Cancer Institute, National Institutes of Health,
Contract grant sponsor: Intramural Program of the National Cancer Institute,
National Institutes of Health; Contract grant number: R01-CA96704; Contract grant
sponsor: Public Health Service Contracts; Contract grant numbers: N01-PC-
67010, N01-PC-67008, N01-PC-67009, N01-PC-65064, N02-PC-71105.
Additional Supporting Information may be found in the online version of this article.
*Correspondence to: Todd M. Gibson, Division of Cancer Epidemiology and
Genetics, Department of Health and Human Services, National Cancer Institute,
National Institutes of Health, 6120 Executive Blvd, Rockville, MD
Conflict of interest: Nothing to report.
Published online 31 March 2012 in Wiley Online Library
1. Friedberg JW. Treatment of follicular non-Hodgkin’s lymphoma: The old and
the new. Semin Hematol 2008;45:S2–S6.
2. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns
by WHO subtype in the United States, 1992–2001. Blood 2006;107:
3. Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients
with recurrent follicular lymphoma: A 20-year study from a single center. J
Clin Oncol 1995;13:140–147.
4. Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of inci-
dence and outcome of transformed non-Hodgkin’s lymphoma. J Clin Oncol
5. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international
prognostic index 2: A new prognostic index for follicular lymphoma developed
by the international follicular lymphoma prognostic factor project. J Clin Oncol
6. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international
prognostic index. Blood 2004;104:1258–1265.
7. Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed
the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447–
8. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma
based on molecular features of tumor-infiltrating immune cells. N Engl J Med
9. de Jong D. Molecular pathogenesis of follicular lymphoma: A cross talk of
genetic and immunologic factors. J Clin Oncol 2005;23:6358–6363.
10. Cerhan JR, Wang S, Maurer MJ, et al. Prognostic significance of host
immune gene polymorphisms in follicular lymphoma survival. Blood 2007;109:
11. Wang SS, Maurer MJ, Morton LM, et al. Polymorphisms in DNA repair and
one-carbon metabolism genes and overall survival in diffuse large B-cell lym-
phoma and follicular lymphoma. Leukemia 2009;23:596–602.
12. Gentles AJ, Alizadeh AA, Lee SI, et al. A pluripotency signature predicts his-
tologic transformation and influences survival in follicular lymphoma patients.
13. Shaffer AL, Wright G, Yang L, et al. A library of gene expression signatures
to illuminate normal and pathological lymphoid biology. Immunol Rev 2006;
14. Bea S, Zettl A, Wright G, et al. Diffuse large B-cell lymphoma subgroups have
distinct genetic profiles that influence tumor biology and improve gene-expres-
sion-based survival prediction. Blood 2005;106:3183–3190.
15. Rudd MF, Sellick GS, Webb EL, et al. Variants in the ATM-BRCA2-
CHEK2 axis predispose to chronic lymphocytic leukemia. Blood 2006;108:
16. Cassar L, Li H, Pinto AR, et al. Bone morphogenetic protein-7 inhibits telo-
merase activity, telomere maintenance, and cervical tumor growth. Cancer
17. Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression.
Cancer Sci 2007;98:621–628.
18. Engelmann A, Speidel D, Bornkamm GW, et al. Gadd45 beta is a pro-survival
factor associated with stress-resistant tumors. Oncogene 2008;27:1429–1438.
19. Bermudez O, Pages G, Gimond C. The dual-specificity MAP kinase phospha-
tases: Critical roles in development and cancer. Am J Physiol Cell Physiol
20. Guda K, Moinova H, He J, et al. Inactivating germ-line and somatic mutations
in polypeptide N-acetylgalactosaminyltransferase 12 in human colon cancers.
Proc Natl Acad Sci USA 2009;106:12921–12925.
21. Brockhausen I. Mucin-type O-glycans in human colon and breast cancer: Gly-
codynamics and functions. EMBO Rep 2006;7:599–604.
22. Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United
States: First report of the national LymphoCare study. J Clin Oncol 2009;27:
23. Wang SS, Menashe I, Cerhan JR, et al. Variations in chromosomes 9 and
6p21.3 with risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers
24. Fritz A, Percy C, Jack A, et al.International Classification of Diseases for
Oncology, 3rd ed. Geneva:World Health Organization; 2000.
25. Bhatti P, Sigurdson AJ, Wang SS, et al. Genetic variation and willingness to
participate in epidemiologic research: Data from three studies. Cancer Epide-
miol Biomarkers Prev 2005;14:2449–2453.
26. Gauderman WJ, Murcray C, Gilliland F, Conti DV. Testing association between dis-
ease and multiple SNPs in a candidate gene. Genet Epidemiol 2007;31:383–395.
27. Benjamini Y, Hochberg Y. Controlling the false discovery rate—A practical and
powerful approach to multiple testing. J R Stat Soc B Met 1995;57:289–300.
726American Journal of Hematology